Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
Jason Margolesky, Carlos Singer
Therapeutic Advances in Neurological Disorders (2017) Vol. 11
Open Access | Times Cited: 21

Showing 21 citing articles:

Parkinson’s Disease
Stephen G. Reich, Joseph M. Savitt
Medical Clinics of North America (2018) Vol. 103, Iss. 2, pp. 337-350
Closed Access | Times Cited: 394
Advanced drug delivery applications of layered double hydroxide
V.K. Ameena Shirin, Renu Sankar, Asha P. Johnson, et al.
Journal of Controlled Release (2020) Vol. 330, pp. 398-426
Closed Access | Times Cited: 214
Recent advancement in synthesis and applications of layered double hydroxides (LDHs) composites
Sundas Riaz, Aziz ur Rehman, Zeenat Akhter, et al.
Materials Today Sustainability (2024) Vol. 27, pp. 100897-100897
Closed Access | Times Cited: 25
Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson’s Disease
Jing Liu, Duyang Gao, Di Hu, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 25
Antiproliferative effects of new magnetic pH-responsive drug delivery system composed of Fe3O4, CaAl layered double hydroxide and levodopa on melanoma cancer cells
Nahid Shahabadi, Mahtab Razlansari, Hossein Zhaleh, et al.
Materials Science and Engineering C (2019) Vol. 101, pp. 472-486
Closed Access | Times Cited: 44
Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients
Kensuke Ikenaka, Yuta Kajiyama, César Aguirre, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
Ke Wang, Junyan Chen, Mingquan Huang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Recent advances in cell membrane-based biomimetic delivery systems for Parkinson’s disease: Perspectives and Challenges
Jasleen Kaur, Abjhishek Thakran, Saba Naqvi
Asian Journal of Pharmaceutical Sciences (2025), pp. 101060-101060
Open Access
Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation
Keyang Li, Yanan Wang, Xu Yatao, et al.
Chinese Chemical Letters (2024) Vol. 35, Iss. 10, pp. 109511-109511
Closed Access | Times Cited: 2
Interaction Studies Between Levodopa and Different Excipients to Develop Coground Binary Mixtures for Intranasal Application
T. Kiss, Tünde Alapi, Gábor Varga, et al.
Journal of Pharmaceutical Sciences (2019) Vol. 108, Iss. 8, pp. 2552-2560
Closed Access | Times Cited: 18
Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence
Thomas Müller
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 397-408
Open Access | Times Cited: 11
Layered Double Hydroxide Nanomaterials: Biomedical Applications, Current Status and Challenges
Ritika Sharma, Bhawna Verma, Sanjeev Kumar, et al.
Nano LIFE (2021) Vol. 11, Iss. 03, pp. 2130008-2130008
Closed Access | Times Cited: 11
Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE‐PD Open‐Label Extension Study
Alberto J. Espay, Robert A. Hauser, Rohit Dhall, et al.
Movement Disorders (2023) Vol. 39, Iss. 2, pp. 428-432
Open Access | Times Cited: 3
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis
Magdalena Żegleń, Katarzyna Śladowska, Paweł Kawalec, et al.
Journal of Comparative Effectiveness Research (2022) Vol. 11, Iss. 12, pp. 889-904
Closed Access | Times Cited: 5
Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa
Samantha Haraszti, Harib Ezaldein, Gregory R. Delost
JAAD Case Reports (2018) Vol. 5, Iss. 1, pp. 21-23
Open Access | Times Cited: 6
CVT-301 for the treatment of Parkinson’s disease
Danielle S. Shpiner, Sagari Betté, Daniel G. Di Luca, et al.
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 7, pp. 603-611
Closed Access | Times Cited: 5
Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease
Mohammad Al Majali, Michael Sunnaa, Pratap Chand
Journal of Geriatric Psychiatry and Neurology (2021) Vol. 34, Iss. 4, pp. 263-273
Closed Access | Times Cited: 5
Combination Therapy with Intravitreal Triamcinolone Acetonide and Oral Levodopa for the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy: A Pilot Study
Hsiu‐Mei Huang, Hsi‐Kung Kuo, Wei‐Yu Chiang, et al.
Journal of Ocular Pharmacology and Therapeutics (2022) Vol. 38, Iss. 2, pp. 167-175
Closed Access | Times Cited: 1
Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
Emelia Priscilla Imbeah, Ofosua Adi‐Dako, Benoit Banga N’guessan, et al.
ADMET & DMPK (2022)
Open Access | Times Cited: 1
OPTIMIZATION THE TREATMENT OF MOTOR FLUCTUATIONS VARIOUS FORMS OF PARKINSON’S DISEASE
К. А. Tarianyk, N. V. Lytvynenko, T. Y. Purdenko, et al.
Bulletin of Problems Biology and Medicine (2022) Vol. 1, Iss. 3, pp. 262-262
Open Access | Times Cited: 1
Поліпшення результатів терапії хвороби Паркінсона за допомогою застосування леводопи пролонгованої дії
Карабань І.М.
Ukrainian Medical Journal (2023) Vol. 153, Iss. 1
Open Access
Page 1

Scroll to top